the first-line maintenance setting via Early Access Programmes (Italy, UK), Temporary Use Authorization (France) or reimbursement following regulatory approval (Italy, UK). Main study endpoint is real-world PFS. Secondary endpoints include overall survival and response rates. The study will also describe surrogate measures of response and tolerability, including time to discontinuation, dose modifications (with reasons) and time to first and second subsequent treatment. Outcomes will be described by key subgroup status pre-index, including performance status, FIGO stage, BRCAm status, debulking surgery outcome and clinical response to chemotherapy. The study aims to include 350 patients. Retrospective data collection began in December 2020 and is planned to end by Q3 2023. As of April 2021, 69 patients have participated.

**UPLIFT (ENGOT-OV67/GOG-3048) A PIVOTAL COHORT OF UPFITAMAB RILSODOTIN, A NAPI2B-DIRECTED ADC IN PLATINUM-RESISTANT OVARIAN CANCER**

1N Concin*, 2,3E Hamilton, 4L Randell, 5B Banejjea, 6Mileshkin, 7RL Coleman, 8S,10,11J Monk, 12,13,14,15,16MR Mirza, 17A Savarese, 19Ray-Coqaud, 23JA Perez Fidalgo, 1PM Bernardos, 1EPutri, 2RBurger, 2RMosher, 1DRichardson, 2DCilibia, 3RMadhy, 21R Chekerov, 21V Van Gorp, 1Medical University of Innsbruck, 1Innsbruck, Austria; 2Department of Obstetrics and Gynaecology, Vienna General Hospital and Innsbruck Medical University, Innsbruck, Austria; 3Sarah Cannon Research Institute, Nashville, United States; 4Tennessee Oncology, Nashville, United States; 5VCU Health System, MCV Physicians, Department of Obstetrics and Gynecology Oncology, Richmond, United States; 6The Royal Marsden NHS Trust, Institute of Cancer Research, London, United Kingdom; 7Peter MacCallum Cancer Centre, Melbourne, Australia; 8Texas Oncology-The Woodlands, The Woodlands, United States; 9GOG Foundation; 10Arizona Oncology, 11US Oncology Network, Phoenix, United States; 12US Oncology, Gynecologic Oncologic Program; 13GOG Partners; 14Righospitalet, Copenhagen, Denmark; 15Nordic Society of Gynaecological Oncology, Clinical Trial Unit, Denmark; 16European Network of Gynaecological Tumor Groups; 17Gynecologic Cancer Inter-Group; 18European Society of Medical Oncology; 19European Society of Gynaecological Oncology; 20Regina Elena National Cancer Institute, Rome, Italy; 21Leon Bérard Center, Lyon, France; 22Hospital Clinic Universitat, Valencia, Spain; 23Mesensa Therapeutics Inc, Cambridge, United States; 24OU Health Stephenson Cancer Center, Oklahoma City, United States; 25Charles University, Czech Republic; 26 Poznan University of Medical Sciences, Poznan, Poland; 27Charte – Universitätsmedizin Berlin, Berlin, Germany; 28IZ Leuven, oncology, Leuven, Belgium

10.1136/ijgc-2021-ESGO.351

**SURGICAL OUTCOME AS PROGNOSTIC FACTOR IN DIFFERENT HISTOLOGIC SUBTYPES OF OVARIAN CARCINOMA: ANALYSIS OF 7 PHASE III TRIALS BY AGO STUDYGROUP + ENGOT**

1F Heitz*, 1,2A Du Bois, 2,3A Reubi, 4J Pujade-Lauraine, 5MR Mirza, 6S Greggi, 7N Colombo, 8C Marth, 9B Vergote, 10P Harter, 11R Ray-Coquaud, 12GBtisens, 13MAgh, 14AC Hardy, 15Sehouli, 16FP Wibmer, 17MEichbaum, 18TGulay, 19W Meier, 20J Pfister. Klinikum Essen-Mitte, Gynecology and Gynecologic Oncology, Dept of Obstetrics & Gynecology, Essen University Hospital, Essen, Germany; 2AGO Study Group, Wiesbaden; 3Philips University Marburg, Coordinating Center for Clinical Trials of the Parallel-University of Marburg, Marburg, Germany; 4GINECO and Hôpital Dieu, Paris, France; 5HGOG & Righospitalet, Dept of Oncology, Copenhagen University Hospital, Copenhagen; 6MITO & Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli, Gynecologic Oncology, Naples, Italy; 7MaNGO & European Institute of Oncology, Gynecologic Oncology, Milano, Italy; 8AGO-A & Innsbruck Medical University, Department of Obstetrics and Gynecology, Innsbruck; 9BGOG & University Hospitals Leuven, Dept of Gynaecological Oncology, Leuven, Belgium; 10GINECO & Centre Leon Bérard Université Claude Bernard Lyon 1, Lyon, France; 11NSGO & Oslo University Hospital, Oslo, Norway; 12University Hospital, LMU Munich, Dept of Obstetrics and Gynecology; 13GINECO & Hôpital Privé des Côtes d’Armor, Pléneuf; 14NOGGO & Charité - Universitätsmedizin Berlin, Campus Virchow, Dpt. Gynecology with Center for Oncological Surgery, Berlin, Germany; 15University Hospital Essen and University Hospital Carl Gustav Carus, TU Dresden, Department of Gynecology and Obstetrics, Dresden; 16Helios Dr. Horst Schmidt Klinik Wiesbaden, Department of Gynecology, Wiesbaden; 17Düsseldorfer University Hospital and Evangelisches Krankenhaus Düsseldorf, Department of Gynecology and Obstetrics, Düsseldorf, Germany; 18Gynecologic Oncology Center, Kiel, Germany

10.1136/ijgc-2021-ESGO.352

**Introduction/Background** Upfitamab rilsodotin (XMT-1536; UpRi), is a first-in-class Dolaflexin antibody-drug conjugate targeting NaPi2b, a sodium-dependent phosphate transport protein broadly expressed in solid tumors including high-grade serous epithelial ovarian cancer (OC). UpRi’s safety and efficacy are being evaluated in a Phase I study (NCT03319628). Preliminary antitumor activity from an expansion cohort of heavily-pretreated OC patients has been reported (Hamilton et al, ESMO 2020). A data-cut of December 2020 demonstrated an ORR of 39% including 2 CRs and DCR of 81% in 26 OC patients with high NaPi2b expression (TPS ≥75). The 2 patients achieving CR had previously been treated with bevacizumab and PARPi (Richardson et al, ASCO 2021, TPS5607). The prevalence of a TPS ≥75 is greater than 60%.

PROC remains a serious unmet medical need as available treatment options provide modest benefit of no more than 12% ORR and median OS less than 12 months. Based on encouraging anti-tumor activity of UpRi, UPLIFT was designed as a Phase 2 single-arm registration strategy for PROC as part of the ongoing study.

**Methodology** The UPLIFT cohort is enrolling patients with platinum resistant high grade serous ovarian, fallopian tube and primary peritoneal cancer with up to 4 prior lines of therapy. Prior bevacizumab is required for patients with 1 or 2 prior lines of therapy but is not required for patients with 3-4 prior lines of therapy. UPLIFT will enroll approximately 180 patients globally for 100 patients with high NaPi2b expression. UpRi is dosed intravenously at 43 mg/m2 every 4 weeks. Patients may enroll regardless of NaPi2b expression and regardless of baseline peripheral neuropathy. Baseline tumor samples (fresh or archived) will be collected for retrospective tumor tissue evaluation of NaPi2b expression.

**Result(s)** The primary objective is assessment of objective response rate in patients with high NaPi2b expression. The cut-off for high NaPi2b expression is TPS ≥75 and was based on data from the expansion cohort. Secondary endpoints include objective response rate in the overall population, duration of response, and adverse events.

**Conclusion** This study is being conducted in collaboration with ENGOT and GOG. Patients will be enrolled globally. (NCT03319628).